MPM Bioimpact LLC Sells 225,780 Shares of Insmed Incorporated (NASDAQ:INSM)

MPM Bioimpact LLC reduced its stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 36.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 389,611 shares of the biopharmaceutical company's stock after selling 225,780 shares during the period. Insmed accounts for 3.8% of MPM Bioimpact LLC's investment portfolio, making the stock its 4th biggest holding. MPM Bioimpact LLC owned 0.22% of Insmed worth $26,899,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Parkman Healthcare Partners LLC grew its holdings in shares of Insmed by 0.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 35,668 shares of the biopharmaceutical company's stock valued at $2,463,000 after acquiring an additional 235 shares in the last quarter. Patient Square Capital LP boosted its holdings in Insmed by 78.9% in the fourth quarter. Patient Square Capital LP now owns 307,167 shares of the biopharmaceutical company's stock worth $21,207,000 after purchasing an additional 135,463 shares in the last quarter. NWI Management LP boosted its holdings in Insmed by 186.0% in the fourth quarter. NWI Management LP now owns 279,000 shares of the biopharmaceutical company's stock worth $19,262,000 after purchasing an additional 181,460 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in Insmed by 19.4% in the fourth quarter. Nuveen Asset Management LLC now owns 1,266,630 shares of the biopharmaceutical company's stock worth $87,448,000 after purchasing an additional 205,473 shares in the last quarter. Finally, Orbimed Advisors LLC bought a new stake in Insmed in the fourth quarter worth $6,528,000.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of recent analyst reports. Wells Fargo & Company upped their price target on shares of Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a report on Wednesday, February 19th. Bank of America upped their price target on shares of Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a report on Thursday, March 20th. Stifel Nicolaus decreased their price target on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a report on Friday, February 21st. Guggenheim restated a "buy" rating and set a $101.00 price target on shares of Insmed in a report on Tuesday, February 25th. Finally, UBS Group decreased their price target on shares of Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Insmed has a consensus rating of "Moderate Buy" and an average price target of $94.63.

Insmed Price Performance

Shares of INSM stock opened at $65.71 on Wednesday. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The stock has a market cap of $11.95 billion, a PE ratio of -11.75 and a beta of 0.84. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm's 50 day moving average price is $72.17 and its two-hundred day moving average price is $73.26.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. During the same quarter last year, the business posted ($1.06) earnings per share. The company's revenue for the quarter was up 22.9% on a year-over-year basis. As a group, analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Buying and Selling

In related news, CEO William Lewis sold 6,830 shares of the firm's stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total value of $479,192.80. Following the completion of the transaction, the chief executive officer now owns 233,924 shares of the company's stock, valued at approximately $16,412,107.84. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Sara Bonstein sold 18,322 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the completion of the transaction, the chief financial officer now directly owns 118,863 shares of the company's stock, valued at approximately $9,545,887.53. This trade represents a 13.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 88,232 shares of company stock worth $6,868,473 over the last ninety days. Company insiders own 3.00% of the company's stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.